Envestnet Asset Management Inc. lifted its stake in Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) by 0.8% in the second quarter, Holdings Channel.com reports. The firm owned 41,308 shares of the company’s stock after buying an additional 341 shares during the period. Envestnet Asset Management Inc.’s holdings in Meridian Bioscience were worth $1,257,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Knowledge Leaders Capital LLC bought a new stake in shares of Meridian Bioscience during the 2nd quarter worth approximately $1,370,000. Arizona State Retirement System lifted its stake in shares of Meridian Bioscience by 6.0% during the 2nd quarter. Arizona State Retirement System now owns 11,800 shares of the company’s stock worth $359,000 after acquiring an additional 664 shares during the last quarter. Versor Investments LP lifted its stake in shares of Meridian Bioscience by 149.7% during the 2nd quarter. Versor Investments LP now owns 29,032 shares of the company’s stock worth $883,000 after acquiring an additional 17,404 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Meridian Bioscience by 41.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 180,170 shares of the company’s stock worth $5,481,000 after acquiring an additional 52,963 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Meridian Bioscience during the 2nd quarter worth approximately $424,000. Hedge funds and other institutional investors own 93.65% of the company’s stock.
Meridian Bioscience Trading Down 0.7 %
Shares of NASDAQ VIVO opened at $31.77 on Wednesday. The company has a quick ratio of 2.36, a current ratio of 3.52 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $31.99 and a two-hundred day simple moving average of $30.87. The firm has a market cap of $1.39 billion, a PE ratio of 32.09 and a beta of 0.28. Meridian Bioscience, Inc. has a twelve month low of $17.20 and a twelve month high of $34.38.
Wall Street Analysts Forecast Growth
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.